|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4908433A
(en)
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
EP0262802A3
(en)
|
1986-09-01 |
1990-01-31 |
Takeda Chemical Industries, Ltd. |
Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
JPH02500329A
(ja)
|
1987-05-21 |
1990-02-08 |
クリエイテイブ・バイオマリキユールズ・インコーポレーテツド |
ターゲット化多機能蛋白質
|
|
US5466447A
(en)
|
1988-06-29 |
1995-11-14 |
Amgen Inc. |
Method for treating psoriasis
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE68927933T2
(de)
|
1988-09-02 |
1997-08-14 |
Dyax Corp |
Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
CA2090473A1
(en)
|
1990-08-29 |
1992-03-01 |
Robert M. Kay |
Homologous recombinatin in mammalian cells
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
CA2100671C
(en)
|
1991-02-27 |
1999-02-02 |
James S. Huston |
Serine rich peptide linkers
|
|
DE69233697T2
(de)
|
1991-03-01 |
2008-01-24 |
Dyax Corp., Cambridge |
Verfahren zur Entwicklung von bindenden Mikroproteinen
|
|
PT100379B
(pt)
|
1991-04-10 |
1999-01-29 |
Scripps Research Inst |
Bibliotecas de receptores heterodimericos usando fagomideos
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
DE69334275D1
(de)
|
1992-08-21 |
2009-05-20 |
Univ Bruxelles |
Immunoglobuline ohne Leichtkette
|
|
WO1995011922A1
(en)
|
1993-10-29 |
1995-05-04 |
Affymax Technologies N.V. |
In vitro peptide and antibody display libraries
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6955807B1
(en)
*
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
KR20070003934A
(ko)
|
2004-03-05 |
2007-01-05 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
|
|
JP2009542592A
(ja)
|
2006-07-06 |
2009-12-03 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
KR100873651B1
(ko)
|
2008-08-21 |
2008-12-11 |
김광한 |
잔디 식재기
|
|
KR101094207B1
(ko)
|
2008-08-21 |
2011-12-14 |
연세대학교 산학협력단 |
Ｔ１―ｔ２ 이중방식 ｍｒｉ 조영제
|
|
KR100996532B1
(ko)
|
2008-08-22 |
2010-11-24 |
주식회사 엠아이텍 |
탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법
|
|
KR101111286B1
(ko)
|
2008-08-22 |
2012-03-14 |
한국생산기술연구원 |
발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치
|
|
WO2010021527A2
(ko)
|
2008-08-22 |
2010-02-25 |
Jung Tae Woo |
영상에 포함된 객체를 색인하는 시스템 및 방법
|
|
CN102197027A
(zh)
|
2008-08-22 |
2011-09-21 |
株式会社Lg化学 |
用于有机电子器件的材料以及使用所述材料的有机电子器件
|
|
WO2010021525A2
(en)
|
2008-08-22 |
2010-02-25 |
Lg Electronics Inc. |
A method for processing a web service in an nrt service and a broadcast receiver
|
|
WO2010021520A2
(ko)
|
2008-08-22 |
2010-02-25 |
엘지전자 주식회사 |
동기 채널 전송 방법
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
|
CN102462837B
(zh)
|
2010-11-19 |
2016-08-03 |
生物林格斯Ip有限公司 |
抗炎组合物
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
EP3443979B2
(en)
|
2011-03-11 |
2026-05-20 |
Assistance Publique - Hôpitaux De Paris |
IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
|
|
US9669071B2
(en)
|
2011-03-11 |
2017-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for stimulating T lymphocytes with IL-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
KR102493543B1
(ko)
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア， インコーポレイテッド |
自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
AU2016246152A1
(en)
|
2015-04-10 |
2017-11-02 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
RU2611685C2
(ru)
|
2015-07-20 |
2017-02-28 |
Илья Владимирович Духовлинов |
Гуманизированное моноклональное антитело, специфичное к синдекану-1
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
CA3032820A1
(en)
|
2016-08-02 |
2018-03-22 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US20200306301A1
(en)
*
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
IL320863A
(en)
|
2017-10-02 |
2025-07-01 |
Visterra Inc |
Antibodies to CD138 and their uses
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
KR20240115352A
(ko)
|
2017-12-06 |
2024-07-25 |
팬디온 오퍼레이션스, 인코포레이티드 |
Il-2 뮤테인 및 그 용도
|
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
US12522640B2
(en)
|
2018-07-24 |
2026-01-13 |
BioNTech SE |
IL2 agonists
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CA3203977A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
WO2022159590A1
(en)
|
2021-01-20 |
2022-07-28 |
Visterra, Inc. |
Interleukin-2 mutants and uses thereof
|
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
CA3243493A1
(en)
|
2022-02-11 |
2023-08-17 |
Visterra, Inc. |
INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|